Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

EPA:ADOC - Euronext Paris - Matif - FR0011184241 - Common Stock - Currency: EUR

4.755  -0.04 (-0.83%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADOC. ADOC was compared to 72 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADOC had negative earnings in the past year.
ADOC had a negative operating cash flow in the past year.
In the past 5 years ADOC always reported negative net income.
In the past 5 years ADOC always reported negative operating cash flow.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

With a Return On Assets value of -87.56%, ADOC is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.56%
ROE N/A
ROIC N/A
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

The Gross Margin of ADOC (264.82%) is better than 100.00% of its industry peers.
ADOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 264.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

More info and screens

0

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADOC has more shares outstanding
Compared to 5 years ago, ADOC has more shares outstanding
ADOC has a better debt/assets ratio than last year.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

ADOC has an Altman-Z score of -2.63. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.63, ADOC is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.63
ROIC/WACCN/A
WACC7.68%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.92 indicates that ADOC may have some problems paying its short term obligations.
ADOC has a worse Current ratio (0.92) than 69.44% of its industry peers.
A Quick Ratio of 0.89 indicates that ADOC may have some problems paying its short term obligations.
The Quick ratio of ADOC (0.89) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.89
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.17%, which is quite impressive.
ADOC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -90.86%.
ADOC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -46.13% yearly.
EPS 1Y (TTM)35.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.24%
Revenue 1Y (TTM)-90.86%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 0.53% on average over the next years.
ADOC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.43% yearly.
EPS Next Y140.65%
EPS Next 2Y33.13%
EPS Next 3Y13.01%
EPS Next 5Y0.53%
Revenue Next Year122.22%
Revenue Next 2Y34.37%
Revenue Next 3Y16.55%
Revenue Next 5Y23.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADOC. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 1.07, the valuation of ADOC can be described as very cheap.
Based on the Price/Forward Earnings ratio, ADOC is valued cheaper than 98.61% of the companies in the same industry.
ADOC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 1.07
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

ADOC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADOC's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.13%
EPS Next 3Y13.01%

More info and screens

0

5. Dividend

5.1 Amount

ADOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (3/7/2025, 7:00:00 PM)

4.755

-0.04 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-14 2025-05-14
Inst Owners7.83%
Inst Owner ChangeN/A
Ins Owners9.04%
Ins Owner ChangeN/A
Market Cap85.97M
Analysts85.71
Price Target9.33 (96.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)63.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)32.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.07
P/S 164.38
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)4.45
Fwd EY93.53%
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.03
BVpS-0.43
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 264.82%
FCFM N/A
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.98%
Cap/Sales 37.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.89
Altman-Z -2.63
F-Score5
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)30.91%
Cap/Depr(5y)56.87%
Cap/Sales(3y)11.2%
Cap/Sales(5y)30.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.24%
EPS Next Y140.65%
EPS Next 2Y33.13%
EPS Next 3Y13.01%
EPS Next 5Y0.53%
Revenue 1Y (TTM)-90.86%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-100%
Revenue Next Year122.22%
Revenue Next 2Y34.37%
Revenue Next 3Y16.55%
Revenue Next 5Y23.43%
EBIT growth 1Y-0.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.26%
EBIT Next 3Y8.66%
EBIT Next 5YN/A
FCF growth 1Y37.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.26%
OCF growth 3YN/A
OCF growth 5YN/A